Table 2.
Patient characteristics of the study population in the first and second supplementary analyses
| SA-1 | SA-2 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4–8 weeks (n = 95) | 8–12 weeks (n = 95) | 4–7 weeks (n = 132) | 7–12 weeks (n = 132) | ||||||||
| Number or mean (sd)† |
(%)† | Number or mean (sd)† |
(%)† | SDif† | Number or mean (sd)† |
(%)† | Number or mean (sd)† |
(%)† | SDif† | ||
| Age | 55.06 (9.29) | 54.05 (8.20) | 0.115 | 54.30 (9.13) | 54.13 (8.54) | 0.019 | |||||
| Gender | Female | 7 | (7) | 6 | (6) | 0.042 | 9 | (7) | 8 | (6) | 0.031 |
| Male | 88 | (93) | 89 | (94) | 123 | (93) | 124 | (94) | |||
| Residency | Non-north | 52 | (55) | 55 | (58) | 0.064 | 76 | (58) | 80 | (61) | 0.062 |
| North | 43 | (45) | 40 | (42) | 56 | (42) | 52 | (39) | |||
| Tumor size | ≤ 5 cm | 47 | (49) | 40 | (42) | 0.148 | 54 | (41) | 53 | (40) | 0.015 |
| > 5 cm | 48 | (51) | 55 | (58) | 78 | (59) | 79 | (60) | |||
| Tumor differentiation | Poorly/undifferentiated | 21 | (22) | 21 | (22) | 0 | 42 | (32) | 36 | (27) | 0.100 |
| Well/moderately | 74 | (78) | 74 | (78) | 90 | (68) | 96 | (73) | |||
| RT delivery | Non-IGRT | 71 | (75) | 72 | (76) | 0.024 | 103 | (78) | 104 | (79) | 0.018 |
| IGRT | 24 | (25) | 23 | (24) | 29 | (22) | 28 | (21) | |||
| Use of PET | No | 10 | (11) | 9 | (9) | 0.035 | 13 | (10) | 16 | (12) | 0.073 |
| Yes | 85 | (89) | 86 | (91) | 119 | (90) | 116 | (88) | |||
| Tumor location | Cervical | ‡ | ‡ | ‡ | ‡ | 0 | ‡ | ‡ | ‡ | ‡ | 0 |
| Non-cervical | ‡ | ‡ | ‡ | ‡ | ‡ | ‡ | ‡ | ‡ | |||
| T-stage | T1-T2 | 9 | (9) | 12 | (13) | 0.101 | 18 | (14) | 16 | (12) | 0.045 |
| T3-T4 | 86 | (91) | 83 | (87) | 114 | (86) | 116 | (88) | |||
| N-stage | Negative | 15 | (16) | 11 | (12) | 0.123 | 16 | (12) | 14 | (11) | 0.048 |
| Positive | 80 | (84) | 84 | (88) | 116 | (88) | 118 | (89) | |||
| Drinking | No | 13 | (14) | 10 | (11) | 0.097 | 16 | (12) | 15 | (11) | 0.024 |
| Yes | 82 | (86) | 85 | (89) | 116 | (88) | 117 | (89) | |||
| Betel nut chewing | No | 45 | (47) | 39 | (41) | 0.127 | 55 | (42) | 55 | (42) | 0 |
| Yes | 50 | (53) | 56 | (59) | 77 | (58) | 77 | (58) | |||
| Smoking | No | 18 | (19) | 14 | (15) | 0.113 | 18 | (14) | 19 | (14) | 0.022 |
| Yes | 77 | (81) | 81 | (85) | 114 | (86) | 113 | (86) | |||
| BMI | 21.85 (3.08) | 22.17 (3.21) | 0.104 | 21.83 (3.39) | 21.80 (3.19) | 0.009 | |||||
| Number of lymph nodes | < 15 | 19 | (20) | 24 | (25) | 0.126 | 33 | (25) | 34 | (26) | 0.017 |
| ≥ 15 | 76 | (80) | 71 | (75) | 99 | (75) | 98 | (74) | |||
| RT dose (Gy) | 47.03 (3.97) | 47.49 (3.71) | 0.120 | 47.56 (3.68) | 47.85 (3.37) | 0.080 | |||||
BMI body mass index, IGRT image-guided radiotherapy, nCCRT neoadjuvant concurrent chemoradiotherapy, PET positron emission tomography, RT radiotherapy, sd standard deviation, SDif standardized difference
†Rounded
‡The exact numbers were not reported because of a Health and Welfare Data Science Center (HWDC) database center policy to avoid numbers in single cells ≤ 2)